GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Cyclically Adjusted PS Ratio

Sino Biopharmaceutical (HKSE:01177) Cyclically Adjusted PS Ratio : 2.04 (As of Jun. 04, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Cyclically Adjusted PS Ratio?

As of today (2024-06-04), Sino Biopharmaceutical's current share price is HK$2.84. Sino Biopharmaceutical's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 was HK$1.39. Sino Biopharmaceutical's Cyclically Adjusted PS Ratio for today is 2.04.

The historical rank and industry rank for Sino Biopharmaceutical's Cyclically Adjusted PS Ratio or its related term are showing as below:

HKSE:01177' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.68   Med: 6.92   Max: 13.52
Current: 2.04

During the past 13 years, Sino Biopharmaceutical's highest Cyclically Adjusted PS Ratio was 13.52. The lowest was 1.68. And the median was 6.92.

HKSE:01177's Cyclically Adjusted PS Ratio is ranked better than
73.41% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs HKSE:01177: 2.04

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sino Biopharmaceutical's adjusted revenue per share data of for the fiscal year that ended in Dec23 was HK$1.543. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is HK$1.39 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sino Biopharmaceutical Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sino Biopharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Cyclically Adjusted PS Ratio Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.06 7.47 4.70 3.57 2.49

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 - 3.57 - 2.49

Competitive Comparison of Sino Biopharmaceutical's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sino Biopharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Cyclically Adjusted PS Ratio falls into.



Sino Biopharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sino Biopharmaceutical's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=2.84/1.39
=2.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical's Cyclically Adjusted Revenue per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Sino Biopharmaceutical's adjusted Revenue per Share data for the fiscal year that ended in Dec23 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=1.543/117.2957*117.2957
=1.543

Current CPI (Dec23) = 117.2957.

Sino Biopharmaceutical Annual Data

Revenue per Share CPI Adj_RevenuePerShare
201412 1.115 99.707 1.312
201512 0.878 102.015 1.010
201612 0.911 103.225 1.035
201712 1.053 104.984 1.176
201812 1.279 107.622 1.394
201912 1.434 110.700 1.519
202012 1.491 109.711 1.594
202112 1.706 112.349 1.781
202212 1.528 114.548 1.565
202312 1.543 117.296 1.543

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sino Biopharmaceutical  (HKSE:01177) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sino Biopharmaceutical Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (HKSE:01177) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
Executives
Tse Eric S Y 2101 Beneficial owner
Tse Ping 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines